Rabeprazole and Domperidone Induced Hyperprolactinemia in a Patient with Type 2 Diabetes Mellitus, Hypothyroidism and Peptic Ulcer Disease: A Case Report
Abstract
Drugs are a common cause of hyperprolactinemia. They are common in patients taking antipsychotics, antiemetics, opioids, antidepressants, prokinetics and proton pump inhibitors (PPI). Rabeprazole is a relatively newer PPI. Domperidone is a well-known prokinetic and antiemetic drug. There are few reports of hyperprolactinemia & galactorrhea with fixed drug combination (FDC) of rabeprazole (20 mg) and domperidone (30 mg). Here, we report a case of 39-year-old diabetic and hypothyroid female patient who was on the above FDC for peptic ulcer disease on and off for the last four years and developed hyperprolactinemia. She showed neither clinical signs of galactorrhea nor amenorrhea. On routine blood investigations, she had increased prolactin level. Radiological evaluation of brain was normal. The drug was stopped and repeat prolactin was normal within one week of withholding. A diagnosis of rabeprazole and domperidone induced hyperprolactinemia was reached based on clinical, laboratory judgement and causality assessment.
Keywords
Full Text:
PDFReferences
Benker G, Jaspers C, Häusler G, Reinwein D. Control of prolactin secretion. Wiener klinische Wochenschrift. 1990; 68(23): 1157-67. DOI: 10.1007/BF01815271
Peveler RC, Branford D, Citrome L, Fitzgerald P, Harvey PW, Holt RI, et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. Journal of Psychopharmacology. 2008; 22(2): 98- 103. DOI: 10.1177/0269881107087346
Soto-Pedre E, Newey PJ, Bevan JS, Greig N, Leese GP. The epidemiology of hyperprolactinaemia over 20 years in the
Tayside region of Scotland: The Prolactin Epidemiology, Audit and Research Study (PROLEARS). Clinical Endocrinology. 2017; 86(1): 60-67. DOI: 10.1111/ cen.13156
Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, Montenegro R Jr, et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. Journal of Endocrinological Investigation.
; 31(5): 436-44. DOI: 10.1007/ BF03346388
Atluri S, Sarathi V, Goel A, Boppana R, Shivaprasad C. Etiological Profile of Galactorrhoea. Indian Journal of Endocrinology and Metabolism. 2018;22(4):489-493. DOI: 10.4103/ijem. IJEM_89_18
Junqueira DR., Bennett D, Huh SY, Comabella CC. Clinical Presentations of Drug-Induced Hyperprolactinaemia: A Literature Review. Pharmaceutical Medicine. 2023;37:153–166.:10.1007/ s40290-023-00462-2
Ashfaq M, Haroon MZ, Alkahraman YM. Proton pump inhibitors therapy and risk of hyperprolactinemia with associated sexual
disorders. Endocrine Regulations. 2022; 56(2): 134-147. DOI: 10.2478/enr-2022-0015
Venkatanarasu A, Boddula R, Basavaraju S, Chinte C, Tickoo V. Drug Induced Hyperprolactinemia. Journal of the Endocrine Society. 2021; 5: A626–7. DOI: 10.1210/jendso/bvab048.1277
Bahar A, Akha O, Kashi Z, Vesgari Z. Hyperprolactinemia in association with subclinical hypothyroidism. Caspian Journal of Internal Medicine. 2011; 2(2): 229-33.
Rasheed HA, Al-Kuraishy HM, Al-Gareeb AI, Hussien NR, Al-Nami MS. Effects of diabetic pharmacotherapy on prolactin hormone in patients with type 2 diabetes mellitus: Bane or Boon. Journal of Advance Pharmaceutical Technology and Research. 2019; 10(4): 163-168. DOI: 10.4103/japtr.JAPTR_65_19
Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clinical Endocrinol (Oxford). 2005; 62(6): 633-43. DOI: 10.1111/j.1365-2265.2005.02243.x
Ashfaq M, M A Abid, K Rauf, Alkahraman YM, Haroon MZ, Ahmad F, et al. Potential Role of Proton Pump Inhibitors Against
Human DRD2 Receptor in Drug Induced Hyperprolactinemia. Revista de Chimie. 2020; 71(10): 182-192. DOI:10.37358/
RC.20.10.8362.
Ortiz-Guerrero G, Amador-Munoz D, Calderon-Ospina CA, Lopez-Fuentes D, Nava Mesa MO. Proton pump inhibitors and dementia: physiopathological mechanisms and clinical consequences. Neural Plasticity. 2018; 5257285. DOI:
1155/2018/5257285
Patrascu OM, Chopra D, Dwivedi S. Galactorrhoea: Report of Two Cases. Maedica (Bucur). 2015; 10(2): 136-139.
Fixed dose combinations approved by DCG(I) since 1961 to 31st December 2019. New Delhi: Central Drug Standard Control Organization; 2023. Available at: https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_
id=MTA1NzY= [accessed on December2023]
Rabeprazole sodium - accessdata.fda.
gov 2013. Maryland: U.S.Food and Drug
Administration; 2013. Available at: https://
www.accessdata.fda.gov/drugsatfda_
docs/label/2013/078964Orig1s000lbl.pdf
[accessed on December 2023]
DOI: https://doi.org/10.15416/pcpr.v9i3.54359
Refbacks
- There are currently no refbacks.
